The Real Marijuana Playbook

Headlines about the Trump Administration’s proposal to move marijuana to Schedule III have generated a lot of excitement. That excitement should be tempered with a realistic timeline, and a clear-eyed plan for what it would actually take to succeed. The opportunity is real, but it will favor teams that pair strategy with economics, regulatory discipline, and patience.

The Federal Register publication is a notice of proposed rulemaking under the Controlled Substances Act. In other words, it is not a final rule. A 90‑day public comment period applies, and no final scheduling decision has been made yet.

The proposed change, from Schedule I to Schedule III, traces back to (1) an August 2023 letter from HHS’s Assistant Secretary for Health and (2) a 2024 memorandum signed by then‑Attorney General Merrick Garland. Both are generally thorough and balanced. However, some Department of Justice language around when HHS determinations are “binding” versus entitled to “significant deference” is confusing, and it underscores the central point: the process is still underway.

Caution is still the watchword. If you want rescheduling to happen, file supportive comments and keep pressure on. History and bureaucratic inertia suggest a final rule could still take years. Acting early, now, can position you to move faster once the regulatory landscape changes.

According to FDA, currently accepted medical uses cited for marijuana and delta‑9 cannabinoids include: (1) anorexia, (2) anxiety, (3) epilepsy, (4) inflammatory bowel disease (IBD), (5) nausea and vomiting, and (6) post‑traumatic stress disorder (PTSD). Not all of these uses have clear, established clinical endpoints, and some reviewing divisions are notoriously challenging regardless of the controlled status of the active ingredient.

Because FDA has already approved two versions of delta‑9 products, you should assess potential FDCA exclusivities early. In some cases, a 505(b)(2) pathway and bridging studies may be available depending on the indication, formulation, and what you can rely on from prior findings.

In parallel, if your product approach is botanical, review FDA’s botanical drug guidance to understand expectations for consistent quality and source control of the API. From there, moving to a final dosage form takes time and disciplined development. The CDMO market is strained right now, so partner selection can be an advantage, or a bottleneck.

Clinical trial design is pivotal. You will need endpoints that are measurable, defensible, and aligned with what regulators expect. Also, sites that run studies involving controlled substances must comply with DEA requirements, which can be burdensome. As a result, not every supportive clinician, or major health system, will be willing to participate.

Clinical trials are expensive, and multi‑site execution is often essential, especially given variability across patients and across the currently accepted medical uses. New entities may need to be created to fund and manage the work. For example, a holding company structure with state‑licensed subsidiaries, and equity alternatives such as phantom stock, may offer practical financing and governance options.

The opportunity is real, but it’s a sophisticated, regulated game. A clear playbook, built early, is what turns a headline into an executable plan.

Value Added Medicines Alliance- We, at VAMA, believe clinical research in this area is vital.  We are happy to discuss these issues, email us at: info@VAMAlliance.org.